The Medicines (MDCO) Earning Somewhat Favorable News Coverage, Accern Reports

News stories about The Medicines (NASDAQ:MDCO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Medicines earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.1656862735572 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Several equities analysts have weighed in on the company. Oppenheimer Holdings, Inc. assumed coverage on The Medicines in a report on Monday, May 22nd. They set a “market perform” rating and a $50.00 price objective for the company. Zacks Investment Research raised The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a report on Tuesday, August 8th. Citigroup Inc. reduced their price objective on The Medicines from $59.00 to $43.00 and set a “neutral” rating for the company in a report on Monday, July 17th. CIBC set a $50.00 price objective on The Medicines in a report on Tuesday, May 23rd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $62.00 price objective on shares of The Medicines in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. The Medicines has an average rating of “Buy” and an average target price of $52.00.

The Medicines (NASDAQ MDCO) opened at 35.40 on Friday. The company’s market capitalization is $2.55 billion. The stock has a 50 day moving average price of $37.77 and a 200-day moving average price of $44.53. The Medicines has a 12-month low of $30.80 and a 12-month high of $55.95.

The Medicines (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($5.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.29) by $4.23. The Medicines had a negative net margin of 670.46% and a negative return on equity of 137.20%. The business had revenue of $18.74 million for the quarter, compared to the consensus estimate of $29.64 million. During the same period in the previous year, the firm earned ($0.62) EPS. The company’s revenue was down 65.8% on a year-over-year basis. Equities analysts predict that The Medicines will post ($9.57) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/18/the-medicines-mdco-earning-somewhat-favorable-news-coverage-accern-reports.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Insider Buying and Selling by Quarter for The Medicines (NASDAQ:MDCO)

What are top analysts saying about The Medicines Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for The Medicines Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit